Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from OMRON ( (JP:6645) ).
OMRON HEALTHCARE Co., Ltd. has announced its decision to initiate a tender offer to acquire shares of Matsuya R&D Co., Ltd., a company listed on the Growth Market of the Tokyo Stock Exchange. This strategic move is part of OMRON HEALTHCARE’s efforts to strengthen its market position and expand its influence in the healthcare sector. The tender offer is contingent upon obtaining necessary approvals under the competition laws of Taiwan and Vietnam, with the process expected to commence around late June 2026. This acquisition is likely to enhance OMRON HEALTHCARE’s capabilities and offerings, potentially impacting stakeholders positively by broadening the company’s market reach and operational scope.
The most recent analyst rating on (JP:6645) stock is a Hold with a Yen4307.00 price target. To see the full list of analyst forecasts on OMRON stock, see the JP:6645 Stock Forecast page.
More about OMRON
OMRON HEALTHCARE Co., Ltd., a subsidiary of OMRON Corporation, is engaged in the development and sale of home-use and medical health devices, health-management software, and health-promotion services. The company is headquartered in Kyoto, Japan, and is led by Ayumu Okada as the Representative Director and President.
YTD Price Performance: -21.48%
Average Trading Volume: 1,347,933
Technical Sentiment Signal: Sell
Current Market Cap: Yen807.4B
See more insights into 6645 stock on TipRanks’ Stock Analysis page.